An October 2020 article entitled “Dissecting the roles of GRK2 and GRK3 in µ-opioid receptor internalization and β-arrestin2 recruitment using CRISPR/Cas9-edited HEK293 cells”, in Scientific Reports describes the generation of clonal-derived, CRISPR engineered GPCR kinases 2 & 3 (GRK2, GRK3) knockout (KO) cell lines for better understanding of µ-opioid (µ-OR) receptor pharmacology.
Despite the plethora of publications citing CRISPR engineering, as of May 2020 a mere 37 papers involved GPCRs (1,2). Even this limited number of reports clearly show the potential impact of CRISPR engineering on GPCR drug discovery (2). The recent study published in Scientific Reports in October 2020 from Moller et al. at the University of Copenhagen describes the use of a comprehensive set of tools, including CRISPR cell engineering, to delineate the roles of GRK2/3 in µ-OR internalization and β-arrestin2 recruitment – processes which have been linked to the development of opioid tolerance (3).
Different µ-OR agonists stimulate specific patterns of receptor phosphorylation and lead to differential cellular outcomes. Previous in vitro and in vivo studies link GRK2 and GRK3 phosphorylation to µ-OR internalization and β-arrestin recruitment. These studies, however, relied on techniques such as short interfering RNA (si-RNA) or overexpression of dominant negative mutants which are susceptible to incomplete KO of GRK activity or undesired effects of overexpression.
The Scientific Reports article describes CRISPR-mediated generation of HEK293 clonal cell lines with the complete KO of GRK2, GRK3 or both, to better understand µ-OR pharmacology. To supplement the CRISPR KO findings, the Brauner-Osborne and Bouvier labs used GRK2 and GRK3 transient expression to reintroduce the deleted protein to show restored function.
Collectively, their studies demonstrate that GRK2 and GRK3 both contribute to agonist-induced β-arrestin2 recruitment and µ-OR internalization for 3 of 4 agonist tested. The exception was morphine, a full agonist of G protein signaling but only a partial agonist of µ-OR internalization and β-arrestin recruitment. The effects of GRK2 and -3 KO were additive, however, receptor internalization was not completely abrogated in the GRK2/3 double KOs suggesting additional factors, such as other GRKs, are involved in µ-OR internalization. The authors also describe a GRK2/3 independent pathway of β-arrestin2 recruitment to the plasma membrane that is observed after prolonged stimulation (60 minutes), particularly at high agonist concentrations.
It’s tools like the clonally-derived, CRISPR engineered GRK2/3 KO cell lines and other innovative tools such as β-arrestin recruitment assays that don’t require GPCR tagging, that are poised to more definitively unravel GPCR signaling and its role in pathophysiology, and ultimately to the development of novel, more efficacious therapeutics.
Don’t allow cell line generation, CRISPR engineering, or high throughput signaling assays to hold your GPCR research back. Multispan has extensive experience with µ-ORs and 240+ other GPCRs. Let our cell lines, signaling assays and cell engineering and assay services advance your GPCR drug development initiatives.
Other Scientific Insights from Multispan:
- Harness the power of CRISPR Engineering. Find out how Multispan solutions ensure production of high quality CRISPR tools.
- The Impact of CRISPR on Accelerating GPCR Drug Discovery. Read a review of how CRISPR technology is strengthening our understanding of GPCR biology, its transformative potential for all phases of GCPR-targeted drug development, and the drivers of successfully implementing CRISPR initiatives.
- Not all cell lines are created equal. Find out why Multispan cell lines outperform.
- Don’t let GPCR tagging bias your results. Find out how to unbias your GPCR signaling research.
- CRISPR: A New Break in the GPCR Drug Development Pipeline. May 2020. https://www.genengnews.com/topics/drug-discovery/crispr-a-new-break-in-the-gpcr-drug-development-pipeline/
- Dissecting the roles of GRK2 and GRK3 in μ-opioid receptor internalization and β-arrestin2 recruitment using CRISPR/Cas9-edited HEK293 cells. Sci. Rep. 2020 Oct 15;10(1):17395. doi: 10.1038/s41598-020-73674-0.
Let’s discuss how MultiScreen™ cell membranes can uniquely empower your program.